Security key
23284F105
CytomX Therapeutics, Inc. - Common Stock (CTMX)
CUSIP: 23284F105
Q1 2022 13F Holders as of 31 Mar 2022
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 53,661,262
- Total 13F value
- $143,355,949
- Share change
- +78,437
- Put/Call ratio
- 68%
- SEC-reported price per share
- $2.67
- Number of holders
- 112
- Value change
- -$1,754,233
- Number of buys
- 51
- Number of sells
- 52
- Shares outstanding
- 217,782,263
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2022
Institutions
112
Top holders
10
CTMX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
CytomX Therapeutics, Inc. SEC filings
CytomX Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 23284F105
Recent filing periods:
Ownership snapshot
Top reported holders of CTMX - CytomX Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Point72 Asset Management,...
Disclosed value leader
Point72 Asset Management,...
Comparable rows
15/15
Latest evidence
31 Dec 2021
13F
Lead comparable stake: 2.9%
Showing 1-6 of 15 holder rows.
Quick read
Point72 Asset Management, L.P. leads the comparable SEC ownership view at 2.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Point72 Asset Management, L.P.'s linked filing trail.
Comparable ownership
Top 5
Point72 Asset Management, L.P.
2.9%
RTW INVESTMENTS, LP
2.8%
BVF INC/IL
2.7%
VANGUARD GROUP INC
2.3%
BlackRock Finance, Inc.
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. |
13F
Company
|
2.9%
|
$27,292,000
6,303,025 shares
|
— | 31 Dec 2021 |
| RTW INVESTMENTS, LP |
13F
Company
|
2.8%
|
$26,109,000
6,029,700 shares
|
— | 31 Dec 2021 |
| BVF INC/IL |
13F
Company
|
2.7%
|
$25,130,000
5,803,700 shares
|
— | 31 Dec 2021 |
| VANGUARD GROUP INC |
13F
Company
|
2.3%
|
$22,118,000
5,107,991 shares
|
— | 31 Dec 2021 |
| BlackRock Finance, Inc. |
13F
Company
|
2.3%
|
$21,488,000
4,962,362 shares
|
— | 31 Dec 2021 |
| ORBIMED ADVISORS LLC |
13F
Company
|
1.5%
|
$13,919,000
3,214,509 shares
|
— | 31 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
112
Shares
53,661,262
Rows available
112
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2022 vs Q1 2022 Across Filers
Q1 2022 holders
112
Q1 2022 holders
112
Holder diff
0
| Investor | Q1 2022 Shares | Q1 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q1 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend